PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28616989-7	2017	YO-PRO1 uptake in cells expressing either the WT or the F288S P2X7 receptor was consistent with recorded membrane current data.	YO-PRO 1	0-7	purinergic receptor P2X 7	Homo sapiens	62-66
26068648-9	2015	P2X(7)R-induced pore formation, assessed by YO-PRO-1 dye uptake, was greater in BMDC, and these cells were protected from cell death.	YO-PRO 1	44-52	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	0-7
26054298-9	2015	Moreover, JNK inhibition decreased supernatant eATP concentration and inhibited Pannexin1 activation, as determined by YoPro-1 uptake in liver cells in a dose-dependent manner.	YO-PRO 1	119-126	mitogen-activated protein kinase 8	Homo sapiens	10-13
26054298-9	2015	Moreover, JNK inhibition decreased supernatant eATP concentration and inhibited Pannexin1 activation, as determined by YoPro-1 uptake in liver cells in a dose-dependent manner.	YO-PRO 1	119-126	pannexin 1	Homo sapiens	80-89
23431238-4	2013	A cytofluorometric assay demonstrated that the P2X7 agonists adenosine-5"-triphosphate (ATP) and 2"(3")-O-(4-benzoylbenzoyl) ATP induced ethidium(+) or YO-PRO-1(2+) uptake into both cell lines.	YO-PRO 1	152-160	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	47-51
24123515-4	2013	We show here, in resting as well as LPS-activated primary microglia, that P2Y6 decreases P2X4-mediated calcium entry and inhibits the dilation of P2X4 channels into a large-conductance pore measured with a YO-PRO-1 uptake assay.	YO-PRO 1	206-214	pyrimidinergic receptor P2Y6	Homo sapiens	74-78
24123515-4	2013	We show here, in resting as well as LPS-activated primary microglia, that P2Y6 decreases P2X4-mediated calcium entry and inhibits the dilation of P2X4 channels into a large-conductance pore measured with a YO-PRO-1 uptake assay.	YO-PRO 1	206-214	purinergic receptor P2X 4	Homo sapiens	146-150
16885537-4	2006	Results showed that HGF suppressed apoptosis in GC and follicle cultures as visualized using apoptosis indicator dye, YO-PRO-1.	YO-PRO 1	118-126	hepatocyte growth factor	Rattus norvegicus	20-23
20529664-6	2010	ATP-induced ethidium+ and YO-PRO-1(2+) uptake were impaired by the P2X7 antagonist, A-438079.	YO-PRO 1	26-34	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	67-71
19226284-5	2009	P2X(7) receptor pharmacology was studied by measuring pore formation in the presence of different agonists and antagonists using the YO-PRO 1 uptake method.	YO-PRO 1	133-141	purinergic receptor P2X 7	Homo sapiens	0-15
17052354-6	2006	Finally, we show that influx of YO-PRO-1, a fluorescent dye used to detect early apoptosis and activation of the purinergic P2X7 receptor channels, is observed after exposure of Jurkat T lymphoblasts to sufficiently large numbers of pulses, suggesting that membrane poration occurs even with nanosecond pulses when the electric field is high enough.	YO-PRO 1	32-40	purinergic receptor P2X 7	Homo sapiens	124-137
22972801-9	2012	Moreover, lipoapoptosis stimulated uptake of a membrane impermeable dye YoPro-1 (indicative of panx1 activation), which was inhibited by panx1 shRNA, probenecid, and mefloquine.	YO-PRO 1	72-79	pannexin 1	Homo sapiens	95-100
22972801-9	2012	Moreover, lipoapoptosis stimulated uptake of a membrane impermeable dye YoPro-1 (indicative of panx1 activation), which was inhibited by panx1 shRNA, probenecid, and mefloquine.	YO-PRO 1	72-79	pannexin 1	Homo sapiens	137-142
22652409-3	2012	A fixed-time flow cytometric assay demonstrated that activation of P2X7 by extracellular ATP induces the uptake of the organic cation, YO-PRO-1(2+), into peripheral blood monocytes from various dog breeds, a process impaired by the specific P2X7 antagonist, A438079.	YO-PRO 1	135-143	purinergic receptor P2X 7	Canis lupus familiaris	67-71
22652409-3	2012	A fixed-time flow cytometric assay demonstrated that activation of P2X7 by extracellular ATP induces the uptake of the organic cation, YO-PRO-1(2+), into peripheral blood monocytes from various dog breeds, a process impaired by the specific P2X7 antagonist, A438079.	YO-PRO 1	135-143	purinergic receptor P2X 7	Canis lupus familiaris	241-245
20670615-9	2010	Moreover, ATP-induced YO-PRO-1(2+) uptake and IL-1beta release were abrogated in cells co-incubated with TGF-beta1.	YO-PRO 1	22-30	transforming growth factor beta 1	Homo sapiens	105-114
19348833-3	2009	MAIN METHODS: P2X7R channel opening was assessed as to the uptake of a marker dye, YO-PRO-1 (YP), in the presence or absence of agonists and antagonists for PPAR gamma under a fluorescence microscope.	YO-PRO 1	83-91	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	14-19
19348833-5	2009	KEY FINDINGS: NSAIDs such as flufenamic acid (FFA) and indomethacin, which are a cyclooxygenase inhibitor and a PPAR gamma agonist, showed enhancing and inhibiting effects on YP uptake at low and high concentrations, respectively, and the enhanced uptake was abolished by periodate-oxidized ATP (oxATP), a selective P2X7R antagonist.	YO-PRO 1	175-177	peroxisome proliferator activated receptor gamma	Mus musculus	112-122
19348833-5	2009	KEY FINDINGS: NSAIDs such as flufenamic acid (FFA) and indomethacin, which are a cyclooxygenase inhibitor and a PPAR gamma agonist, showed enhancing and inhibiting effects on YP uptake at low and high concentrations, respectively, and the enhanced uptake was abolished by periodate-oxidized ATP (oxATP), a selective P2X7R antagonist.	YO-PRO 1	175-177	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	316-321
19348833-6	2009	The PPAR gamma agonists 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone decreased the basal and FFA-enhanced YP uptake, while the antagonist GW9662 increased YP uptake, this effect being blocked by the agonists and also by oxATP.	YO-PRO 1	118-120	peroxisome proliferator activated receptor gamma	Mus musculus	4-14
18942742-6	2009	Primary mouse astrocytes were found to take up the P2X7R permeant dyes YO-PRO-1 (YP) and propidium iodide in absence of any added ligands.	YO-PRO 1	71-79	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	51-56
14978243-6	2004	The mutant subunits also suppressed the P2X7-dependent pore formation as assessed by uptake of the propidium dye YO-PRO-1 (Molecular Probes, Eugene, OR) in response to 2",3"-O-(4-benzoyl)-benzoyl-ATP (BzATP) in transfected human embryonic kidney 293 cells.	YO-PRO 1	113-121	purinergic receptor P2X 7	Homo sapiens	40-44
15991050-5	2005	Synthesis of the P2 X(7) receptor by these cells has been established by reverse transcriptase-polymerase chain reaction, immunohistochemistry, immunocytochemistry and cellular accumulation of the fluorescent DNA-binding dye YO-PRO-1.	YO-PRO 1	225-233	purinergic receptor P2X 7	Homo sapiens	17-33
15456831-6	2004	Among them, only high concentrations of ATP (500 microM) and BzATP (2",3"-O-(4-benzoyl-benzoyl)-ATP triethylammonium) (100 microM) were able to induce accumulation of YO-PRO-1 in the GCL and in the nerve fiber layer, suggesting that different cell types were responding to P2X7 stimulation.	YO-PRO 1	167-175	germ cell-less 1, spermatogenesis associated	Rattus norvegicus	183-186
15472991-6	2005	IL-1beta also induced the formation of membrane pores as evidenced by the uptake of YO-PRO-1 (375 Da).	YO-PRO 1	84-92	interleukin 1 beta	Homo sapiens	0-8
35489662-8	2022	Keap1-Nrf2-ARE and apoptosis signaling pathways were measured by Western blot, RT-PCR, and YO-PRO-1 staining in kidneys or NRK52E cells.	YO-PRO 1	91-99	Kelch-like ECH-associated protein 1	Rattus norvegicus	0-5
9716185-4	1998	Activation of Mr 40,000 and Mr 52,000 kinases is also prominent by 12-16 h. The modulation of all these kinases coincided with the activation of caspase-3 at 12 h and the appearance of a population of apoptotic cells that accumulate YO-PRO-1, are susceptible to the caspase inhibitor carbobenzoxy-L-aspartyl-alpha-[(2,6-dichloro-benzoyl)oxy]methane, and contain fragmented genomic DNA.	YO-PRO 1	233-241	caspase 3	Homo sapiens	145-154
30796903-10	2019	Hek293-P2X7R but not untransfected Hek293 cells could take up of YO-PRO-1.	YO-PRO 1	65-73	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	7-12
30796903-11	2019	In addition, the uptake of YO-PRO-1 by Hek293-P2X7R was blocked by oxATP, a P2X7 antagonist and CBX, a pannexin1 inhibitor.	YO-PRO 1	27-35	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	46-51
30796903-11	2019	In addition, the uptake of YO-PRO-1 by Hek293-P2X7R was blocked by oxATP, a P2X7 antagonist and CBX, a pannexin1 inhibitor.	YO-PRO 1	27-35	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	46-50
30796903-11	2019	In addition, the uptake of YO-PRO-1 by Hek293-P2X7R was blocked by oxATP, a P2X7 antagonist and CBX, a pannexin1 inhibitor.	YO-PRO 1	27-35	pannexin 1	Mus musculus	103-112
30545933-2	2019	ATP-induced responses were measured in stable cell lines overexpressing human P2X4 using a YOPRO-1 dye uptake assay, intracellular calcium measurements, and whole-cell patch-clamp recordings.	YO-PRO 1	91-98	purinergic receptor P2X 4	Homo sapiens	78-82